Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANT-1403 in Primary Axillary Hyperhidrosis
NCT01799824Phase 2
Key facts
- Status
- Completed
- Start
- Feb 2013
- Primary completion
- Jul 2013
- Countries
- 1
- Sponsor
- Anterios, Inc.
- Modality
- Recombinant Proteins and Enzymes
- Drugs
- ANT-1403
- Conditions
- primary axillary hyperhidrosis (PAH)
01
Overview
Phase 2, randomised, double-blind trial of ANT-1403 in primary axillary hyperhidrosis (PAH) (2 arms), sponsored by Anterios, Inc. Primary endpoint: Hyperhidrosis Disease Severity Scale at Week 8. Started Feb 2013; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Active
ANT-1403
Vehicle
Placebo Vehicle
03
Endpoints
Primary
Hyperhidrosis Disease Severity Scale
Secondary
Gravimetric Sweat Production
Beyond the preview
Go deeper on NCT01799824.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01799824.